Balance Sheet Details

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Prepaid Expenses

Prepaid expenses consisted of the following:


	March 31, 2026		December 31, 2025
Prepaid research and development expenses	$	489	$	106
Prepaid insurance	109		438
Prepaid professional fees	196		371
Prepaid other	239		154
Total prepaid expenses	$	1,033	$	1,069

Accrued Liabilities

Accrued liabilities consisted of the following:


	March 31, 2026		December 31, 2025
Accrued research and development costs	$	1,251	$	1,522
Accrued professional fees	1,208		764
Accrued other	117		41
Total accrued liabilities	$	2,576	$	2,327

PanCAN Grant Agreement

In 2023, we were selected by the Pancreatic Cancer Action Network (“PanCAN”), a not-for-profit entity, as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to $5,000 in funding for eligible research expenses, and we must comply with the conditions set out in the award agreement, including providing periodic performance progress reports.

Funding received for the three months ended March 31, 2026 and 2025 was nil. During the three months ended March 31, 2026 and 2025, we recognized $390 and $756, respectively, as a reduction of research and development expenses based on eligible costs incurred in accordance with the agreement.

As of March 31, 2026 and December 31, 2025 eligible research and development expenditures incurred exceeded cumulative funding received to date, resulting in other receivables of $917 and $527, respectively.